Difference between revisions of "Programmed death-ligand 1"
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
==General== | ==General== | ||
*[[IHC]] testing using a PD-L1 antibody predicts response to | *[[IHC]] testing using a PD-L1 antibody predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/> | ||
==Prognosis== | ==Prognosis== | ||
Revision as of 03:49, 4 May 2016
Programmed death-ligand 1, commonly abbreviated PD-L1, is protein with an important role in immune system regulation, and thus cancer aggressiveness.
It is also known as CD274.[1]
General
Prognosis
- Good prognosis - in high-grade ovarian serous carcinoma, associated with tumour-infiltrating lymphocytes.[3]
Drugs
- Atezolizumab.[2]
Application of PD-L1 antibodies
PD-L1 antibodies are being used to treat:[4]
- Malignant melanoma.
- Non-small cell lung cancer.
- Associated with response predicted by tumour-infiltrating lymphocytes and PD-L1 IHC positivity of the tumour cells.[2]
- Renal cell carcinoma.
See also
References
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 605402
- ↑ 2.0 2.1 2.2 Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D. et al. (Mar 2016). "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.". Lancet. doi:10.1016/S0140-6736(16)00587-0. PMID 26970723.
- ↑ Webb, JR.; Milne, K.; Kroeger, DR.; Nelson, BH. (May 2016). "PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.". Gynecol Oncol 141 (2): 293-302. doi:10.1016/j.ygyno.2016.03.008. PMID 26972336.
- ↑ Gandini, S.; Massi, D.; Mandalà, M. (Apr 2016). "PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.". Crit Rev Oncol Hematol 100: 88-98. doi:10.1016/j.critrevonc.2016.02.001. PMID 26895815.